Recordati: Recordati's Acquisition of Enjaymo Rights From Sanofi
Hogan Lovells has advised Recordati on the deal. Recordati has acquired global rights to Enjaymo from Sanofi for a consideration of US$825 million plus additional commercial [...]
Read full article »
Recordati engages in the research, development, manufacture, marketing and sale of pharmaceutical drugs for the treatment of rare diseases.
Read more